Real-time PCR technology for cancer diagnostics

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1178-1185

  Bernard, Philip S ^a   Wittwer, Carl T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MOLECULAR MARKER; PROTEIN P53; RNA; TUMOR MARKER;

ALGORITHM; CANCER DIAGNOSIS; DNA MICROARRAY; HUMAN; MUTATION; ONCOGENE NEU; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVIEW; RNA ANALYSIS;

EID: 0036320413     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1178     Document Type: Review

References (77)

1. Molecular portraits of human breast tumours
2. Gene expression profiling predicts clinical outcome of breast cancer
3. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
4. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
5. Diversity of gene expression in adenocarcinoma of the lung
6. Molecular cytogenetics of primary breast cancer by CGH
7. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization
8. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer
9. Comparative genetic patterns of glioblastoma multiforme: Potential diagnostic tool for tumor classification
10. Genomic aberrations and survival in chronic lymphocytic leukemia
11. FISH monitoring of 100 courses of human leukemias: The cytogenetic viewpoint
12. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction
13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
14. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer
15. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia
16. Epstein-Barr viral load measurement as a marker of EBV-related disease
17. DNA methylation, chromatin inheritance, and cancer
18. Cancer susceptibility and the functions of BRCA1 and BRCA2
19. p53 and human cancer: The first ten thousand mutations
20. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization
21. Functional discovery via a compendium of expression profiles
22. Cluster analysis and display of genome-wide expression patterns
23. Gene-expression profiles in hereditary breast cancer
24. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
25. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
26. Detection of p53 by rapid PCR-SSCP and its association with poor survival in breast cancer
27. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
28. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome
29. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
30. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas
31. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
32. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
33. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
34. p53 mutation in plasma and its prognostic value in breast cancer patients
35. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance
36. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
37. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
38. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
39. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
40. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
41. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases
42. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
43. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays
44. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
45. Emerging homogeneous DNA-based technologies in the clinical laboratory
46. Real-time PCR
47. Continuous fluorescence monitoring of rapid cycle DNA amplification
48. Quantification on the LightCycler
49. Laser-capture microdissection: Opening the microscopic frontier to molecular analysis
50. Genome-wide analysis of DNA copy-number changes using cDNA microarrays
51. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer
52. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
53. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
54. Color multiplexing hybridization probes using the apolipoprotein E locus as a model system for genotyping
55. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
56. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
57. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies
58. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
59. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
60. Detection of mitochondrial DNA mutations by temporal temperature gradient gel electrophoresis
61. Enzymatic and chemical cleavage methods
62. Validation of fluorescent SSCP analysis for sensitive detection of p53 mutations
63. Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography
64. Rapid F508del and F508C assay using fluorescent hybridization probes
65. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR
66. Evaluation of the Roche Diagnostics LightCycler-Factor V Leiden mutation detection kit and the LightCycler-prothrombin mutation detection kit
67. 1-antitrypsin genotyping by multiplex real-time fluorescence PCR with the LightCycler
68. Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes
69. Evaluation of the apo E genotyping kit on the LightCycler
70. In-tube DNA methylation profiling by fluorescence melting curve analysis
71. Fluorescein-labeled oligonucleotides for real-time PCR: Using the inherent quenching of deoxyguanosine nucleotides
72. American Joint Committee on Cancer prognostic factors consensus conference
73. STI571: A paradigm of new agents for cancer therapeutics
74. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
75. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer
76. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers
77. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18